Bicycle Therapeutics (BCYC) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking.

Do institutionals & insiders have more ownership in RXRX or BCYC?

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in RXRX or BCYC?

Bicycle Therapeutics received 111 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 70.50% of users gave Bicycle Therapeutics an outperform vote while only 55.56% of users gave Recursion Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Recursion Pharmaceuticals	Outperform Votes 30 55.56%	Underperform Votes 24 44.44%
Bicycle Therapeutics	Outperform Votes 141 70.50%	Underperform Votes 59 29.50%

Which has more risk & volatility, RXRX or BCYC?

Recursion Pharmaceuticals has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Which has higher valuation and earnings, RXRX or BCYC?

Bicycle Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$58.49M	42.41	-$328.07M	-$1.66	-3.72
Bicycle Therapeutics	$35.28M	17.13	-$180.66M	-$2.88	-3.03

Does the media prefer RXRX or BCYC?

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 7 mentions for Recursion Pharmaceuticals and 5 mentions for Bicycle Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 0.97 beat Bicycle Therapeutics' score of 0.94 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Bicycle Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is RXRX or BCYC more profitable?

Bicycle Therapeutics has a net margin of -450.64% compared to Recursion Pharmaceuticals' net margin of -579.52%. Bicycle Therapeutics' return on equity of -27.35% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-579.52%	-76.56%	-55.68%
Bicycle Therapeutics	-450.64%	-27.35%	-20.81%

Do analysts recommend RXRX or BCYC?

Recursion Pharmaceuticals currently has a consensus target price of $8.25, suggesting a potential upside of 33.71%. Bicycle Therapeutics has a consensus target price of $29.14, suggesting a potential upside of 233.82%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicycle Therapeutics is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Bicycle Therapeutics	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Bicycle Therapeutics beats Recursion Pharmaceuticals on 11 of the 18 factors compared between the two stocks.